相关实验视频
Updated: Jun 23, 2025

05:50
Ameliorating Osteoarthritis in Mice Using Silver Nanoparticles
Published on: June 2, 2023
1.1K
基于植物成分的纳米治疗方法,有效管理关节炎症状况:关节炎
Jyotsna Kharbanda1, Rupa Mazumder1, Snigdha Bhardwaj1
1Noida Institute of Engineering and Technology (Pharmacy Institute), 19 Knowledge Park-2, Greater Noida, Uttar Pradesh, 201306, India.
Current drug targets
|June 16, 2024
概括
纳米技术增强了天然的抗炎化合物 (植物成分) 以改善关节炎治疗. 这种方法改善了药物输送,并针对多种疾病途径,为传统疗法提供了有希望的替代方案.
科学领域:
- * 药理学和纳米医学
- * 风湿病学和天然产品化学
背景情况:
- * 由于传统治疗的局限性和不良影响,关节炎管理面临挑战.
- *植物成分显示出抗炎和关节保护作用的希望,但其生物可用性较差.
- *纳米技术提供了一种新的方法来克服关节炎治疗中的这些局限性.
研究的目的:
- * 审查纳米治疗方法与植物成分相结合的潜力,以改善关节炎管理.
- * 探索纳米载体如何增强天然抗关节炎化合物的输送和有效性.
- * 总结植物成分纳米配方在治疗关节炎中的作用机制.
主要方法:
- * 关于植物成分,纳米技术和关节炎的综合文献评论.
- *分析纳米载体系统 (脂质体,纳米颗粒) 用于植物成分的输送.
- * 检查关键植物成分 (黄素,黄素,黄素) 和它们的纳米配方的抗关节炎机制.
主要成果:
- *纳米载体显著提高了植物成分的生物可用性和药理动力学.
- *纳米配制的植物成分有效地向多种关节炎途径,包括炎症和软骨退化.
- * 关键的植物成分如黄素,白醇和氨酸在纳米封装时表现出强大的抗炎和免疫调节作用.
结论:
- *将植物成分与纳米技术相结合,为开发有针对性和有效的关节炎疗法提供了一个强大的策略.
- *纳米治疗方法克服了天然化合物的固有局限性,提高了它们的临床效用.
- * 本综述强调了创新性关节炎治疗开发的有希望的途径,有利于研究人员和临床医生.
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
125
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
125
Inflammatory Response
2.0K
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
2.0K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
130
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
130
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
156
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
156
The JAK-STAT Signaling Pathway
8.8K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.8K
T Cell Types and Functions
999
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
999

